Dose reduction strategy can substantially reduce high cost of TNF inhibitor therapy in RA

 

  • Good clinical response to TNFi maintained when dose reduced by one-third

 

Rome, Italy (13 June 2015) – The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.


Reducing the TNFi dose by two-thirds resulted in more flares (exacerbations of symptoms and signs) but these subsided when the higher dose of TNFi was restarted, and did not adversely affect subsequent progression of any disability. In some cases however, patients maintained a clinical response after stopping the TNFi altogether.

 

"The optimal management of RA involves achieving the lowest possible disease activity – ideally remission, and then maintaining this level of control," said lead author, Dr. James Galloway, Department of Rheumatology, King’s College Hospital NHS Foundation Trust, UK. "Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy."

 

RA is a chronic inflammatory disease characterised by joint inflammation and damage, functional disability and significantly increased mortality. Early intervention using a conventional synthetic disease-modifying anti-rheumatic drug (DMARD) such as methotrexate is critical in preventing structural joint damage and progressive loss of function. For those patients who either fail to respond, or who develop an inadequate response to these drugs over time, a biologic DMARD is an effective add-on treatment option.2 The first choice of biologic therapy is usually a TNFi2 and currently identical dosing regimens of TNFi are used both to induce and then maintain a clinical response.1

 

Over the first six months of the study, flares (exacerbations of symptoms and signs) occurred in 14% of patients who stayed on the same TNFi dose, compared to a similar figure of 13% in those patients for whom the dose was reduced by one-third. A two-thirds dose reduction increased the odds of a flare occurring by four times compared with a one-third dose reduction, with flares occurring in 37% of patients. Post-dose reduction flares resolved when the original dose of TNFi was restarted. There were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.

 

The OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD. To be eligible, patients had to demonstrate stable low disease activity (DAS28 less than 3.2) for over three months. Patients with serious concomitant illness, or those taking high-dose steroids (more than 10mg prednisolone daily) were excluded.

 

Of the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.

 

 

 

 

  • Abstract Number: SAT0150

 

 

About EULAR

 

The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.

 

EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.

 

With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 19 health professionals associations and 21 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care.

 

EULAR 2015 is set to be the biggest rheumatology event in Europe with around 14,000 scientists, physicians, allied health professionals and related audiences in attendance from more than 120 countries. Over the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers.

 

 

 


European League Against Rheumatism, 13.06.2015 (tB).

MEDICAL NEWS

New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…

ERNÄHRUNG

Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…
Mehr Lebensqualität für onkologische Patient:innen durch bessere Versorgung: Supportivtherapie, Präzisionsonkologie,…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver

MULTIPLE SKLEROSE

Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…